✦ LIBER ✦

780 A CLINICAL STUDY ON ANTI-HBV-DC-MTL COMBINED WITH TELBIVUDINE IN THE HBeAg POSITIVE CHRONIC HEPATITIS B VIRUS INFECTION

✍ Scribed by Wu, B.-F.; Yang, J.-Y.; Liu, Y.; Wang, X.-Q.; Huang, X.-H.; Xiao, Z.-S.; Li, X.-S.; Yang, M.; Zhou, Y.; Yang, J.; Li, F.-Q.; Huang, H.; Qiu, Q.-M.

Book ID: 123280949
Publisher: Elsevier Science
Year: 2013
Tongue: English
Weight: 167 KB
Volume: 58
Category: Article
ISSN: 0168-8278
DOI: 10.1016/S0168-8278(13)60782-5

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

781 A CLINICAL TRIAL ON ANTI-HBV-DC VACC

781 A CLINICAL TRIAL ON ANTI-HBV-DC VACCINE COMBINED WITH LAMIVUDINE AND THYMOSIN-a1 IN THE HBeAg POSITIVE PATIENTS OF CHRONIC HEPATITIS B VIRUS INFECTION

✍ Wu, B.-F.; Yang, J.-Y.; Zhang, Y.-L.; Liu, Y.; Zhou, H.-H.; Wang, X.-Q.; Li, F.- 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 67 KB

A dose-finding study of once-daily oral

A dose-finding study of once-daily oral telbivudine in HBeAg-positive patients with chronic hepatitis B virus infection

✍ Ching-Lung Lai; Seng Gee Lim; Nathaniel A. Brown; Xiao-Jian Zhou; Deborah M. Llo 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 305 KB 👁 1 views

Current therapy for chronic hepatitis B is suboptimal as a result of limited durable response rates, cumulative viral resistance, and/or poor tolerability. Telbivudine has potent antiviral activity against hepatitis B virus (HBV) in vitro and in the woodchuck model and has a promising preclinical sa

Adefovir and lamivudine in combination c

Adefovir and lamivudine in combination compared with adefovir monotherapy in HBeAg-negative adults with chronic hepatitis B virus infection and clinical or virologic resistance to lamivudine: A retrospective, multicenter, nonrandomized, open-label study

✍ Adriano M. Pellicelli; Giuseppe Barbaro; Ruggiero Francavilla; Mario Romano; Gio 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 536 KB

1171 Molecular epidemiology of hepatitis

1171 Molecular epidemiology of hepatitis B virus in patients with HBEAG-negative/anti-HBE-positive chronic hepatitis B from different geographical areas. Data from the PEGASYs® study in HBE-antigen-negative CHB

✍ BRUNETTO, M; MAINA, A; OLIVERI, F; BONINO, F; COLUCCI, G; MARCELLIN, P; LAU, G; 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 152 KB

421 A new bio-mathematical model to desc

421 A new bio-mathematical model to describe the dynamics of HBV-DNA and infected hepatocytes in HBEAG-negative/anti-HBE-positive chronic hepatitis B patients treated with peginterferon alfa-2A (40KD) (PEGASYS®), lamivudine, or PEGASYS® plus lamivudine combin

✍ P. Colombatto; R. Bizzarri; L. Civitano; F. Oliveri; F. Bonino; G. Germanidis; P 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 64 KB

1181 A phase III, partially double-blind

1181 A phase III, partially double-blinded study evaluating the efficacy and safety of peginterferon alfa-2A (40KD) (PEGSYS®) alone or in combination with lamivudine vs lamivudine in 546 patients with HBEAG-negative/anti-HBE-positive chronic hepatitis B

✍ MARCELLIN, P; LAU, G; BONINO, F; FARCI, P; HADZIYANNIS, S; JIN, R; LU, Z; PIRATV 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 214 KB